Biodesix, Inc.’s Post

January is Thyroid Awareness Month. Join us in spreading education about thyroid cancer, which is estimated to be diagnosed in more than 43,000 people each year¹. This infographic ², derived exclusively from NeoGenomics data, shares insights about the disease – and underscores the importance of precision medicine. Equipping physicians and pharmaceutical partners with cancer tests that enable precision medicine can unlock targeted treatment options for patients. #NeoGenomics #ThyroidAwarenessMonth #ThyroidCancer #CancerTesting Sources: 1= American Cancer Society; 2= NeoGenomics Data

Aptamers can bind to a diverse range of targets, making them an alternative to traditional antibodies for a range of research, diagnostic, and therapeutic applications. Optimers® are customized next-generation aptamers that demonstrate significant potential. They possess affinity, specificity, and stability that can be developed towards a broad range of novel and validated biomarkers. In this webinar brought to you by Aptamer Group, David Bunka will discuss the development and use of Optimers for developing cancer treatments and diagnostics. Register now: https://ow.ly/tiLG50RwaKY

If you missed our webinar, A New Frontier in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Biomarker Testing, you can view it with the link below. The webinar explores the role cfHPV-DNA plays in cancer prognosis, and what barriers biopharma companies face in incorporating cfHPV-DNA into their clinical trial design. The speakers discuss how pharma manufacturers, HCPs and patients can collaborate to help overcome these barriers. #HPV #CancerResearch https://hubs.la/Q02kBkYH0

On demand webinar on organoid drug screening! Click below to access. #OncoPro #Oncology #3Dmodeling

Ovarian Cancer Diagnostics Global Market Report 2024 Global ovarian cancer diagnostics market size is expected to reach $3.65 Bn by 2028 at a rate of 6.7%, segmented as by product type, instruments, kits, reagents Read More @ https://lnkd.in/dxiP8XTq #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel

In case you missed our webinar, A New Frontier in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Biomarker Testing, you can view it with the link below. The webinar explores the role cfHPV-DNA plays in cancer prognosis, and what barriers biopharma companies face in incorporating cfHPV-DNA into their clinical trial design. The speakers discuss how pharma manufacturers, HCPs and patients can collaborate to help overcome these barriers. #HPV #CancerResearch https://hubs.la/Q02kM-g50

Very interesting webinar on the latest advancements in gastric cancer biomarkers for pathologists!

🔎 PROTEINA Case Study: Unveiling BCL2 PPI network 🔬 Discover our approach to investigating BCL2 PPI biomarkers to reveal the therapeutic impact of Venetoclax, the first FDA-approved BCL2 inhibitor, in transforming the treatment of hematologic malignancies. 📣 Takeaway: Assessing the efficacy of anti-cancer treatment has been always a primary objective for cancer drug developers. Our innovative SPID platform allows in-depth analysis of 47 distinct metrics including 20 different protein-protein interactions within the BCL2 family, providing a thorough quantitative assessment of apoptosis signaling from clinical samples of patients undergoing treatment. Check out the poster below to find out more about PROTEINA’s discovery, presented by our chief scientist, Byoungsan Choi at #AACR2024. Read a full abstract by clicking here: https://lnkd.in/gcJ7knrr   #PROTEINA #SPIDPlatform #CaseStudy #PPIBiomarker #BCL2Inhibitor #BCL2Family #MultipleMyeloma #Venetoclax  

This PeerView Live Peer Pressure educational symposium presented at the annual #ASCO meeting in Chicago will provide updates on the latest practice-changing data on neoadjuvant, adjuvant, and #radioligand #immunotherapy in #prostatecancer along with an expert-led discussion of the implications for practice. Various real-world case scenarios will be explored to highlight the challenges and practical considerations of integrating immunotherapy into the treatment continuum and demonstrate how to implement new standards of care to improve patient outcomes in prostate cancer. Featuring Karim Fizazi, MD, PhD, Pedro C Barata, MD MSc FACP, Kim N. Chi, MD, FRCPC, and Alicia K. Morgans, MD, MPH, this event will be presented on June 1st during #ASCO24: #ProstateCancer #MedEd. https://lnkd.in/etYGCr37 This activity has been supported by educational grants from Astellas Pharma and Pfizer, Bayer, The Janssen Pharmaceutical Companies of Johnson & Johnson, and Novartis.

#NCEMinus1Opportunity #alert Watch this video for more information about the NCE minus one opportunity for the molecule #Truqap to treat breast cancer that meets certain disease criteria. If you want to know more about this NCE minus 1 opportunity or want to conduct comprehensive research on the potential of this opportunity, write to us at bd@springbiosolution.com Visit us at https://lnkd.in/dw2U7yCr to learn more about us and our team. Check all the NCE minus 1 videos from 2023 here: https://lnkd.in/gF3Z3Yf5 Nikhila Shashikanth I Vrishali Sekhar I Pramila Coutinho I Vikrant Chudasama I Priyanka Kochrekar I Falak khan I Priyanka Ganeriwal I Shreyas Shendge I Akhilesh Chaudhari I Anuja Pandit | Ingrid Hoyos #SpringBioSolution #SpringBio #NCEMinus1 #NCEMinus1Opportunity #drugdiscovery #drugdevelopment #drugresearch #rlddrugs #genericmedicines #genericdrugs #clinicaltrials #pharma #pharmaindustry #pharmainnovation